Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Crossref DOI link: https://doi.org/10.1186/s12916-017-0902-9
Published Online: 2017-07-21
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kemp, Robert
Prasad, Vinay
